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Objectives. The study aimed at describing characteristics and outcome of tuberculous meningitis (TBM) in HIV-positive patients
and comparing these parameters with those of extrapulmonary TB (TBEP) and pulmonary TB (TBP). Methods. Kaplan-Meier
estimation and Poisson regression models were used to assess the mortality following TB diagnosis and to evaluate potential
prognostic factors for the 3 groups of TB patients separately. Results. A total of 100 patients with TBM, 601 with TBEP, and 371
TBP were included. Patients with TBM had lower CD4 cell counts and only 17.0% received antiretroviral therapy (ART) at TB
diagnosis. The cumulative probability of death at 12 months following TB was 51.2% for TBM (95% CI 41.4–61.6%), 12.3% for TBP
(8.9–15.7%), and 19.4% for TBEP (16.1–22.6) (𝑃 < 0.0001; log-rank test). For TBM, factors associated with a poorer prognosis were
not being on ART (adjusted incidence rate ratio (aIRR) 4.00 (1.72–9.09), a prior AIDS diagnosis (aIRR = 4.82 (2.61–8.92)), and
receiving care in Eastern Europe (aIRR = 5.41 (2.58–11.34))). Conclusions. TBM among HIV-positive patients was associated with
a high mortality rate, especially for patients from Eastern Europe and patients with advanced HIV-infection, which urgently calls
for public health interventions to improve both TB and HIV aspects of patient management.
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1. Introduction
Tuberculous meningitis (TBM) is one of the most devastat-
ing manifestations of extrapulmonary tuberculosis (TBEP)
and is associated with severe morbidity and high mortality
[1]. HIV-positive individuals are known to be at increased
risk of developing TBEP including TBM, particularly those
patients with more advanced levels of immunodeficiency [2–
4]. Further, it has been shown that TBM amongHIV-positive
patients in the period prior to combination antiretroviral
therapy (cART) had highermortality rates compared toHIV-
negative individuals [3, 5].
Establishment of a TB diagnosis in HIV-positive patients
poses a clinical challenge.This is true for both pulmonary TB
(TBP) andTBEP and perhaps especially so for a TBMdiagno-
sis [6]. Early diagnosis is important because it improves the
overall prognosis; however, identification of acid-fast bacilli
in the cerebrospinal fluid (CSF) and culture ofMycobacterium
tuberculosis (Mtb) lacks sensitivity, and therefore a TBM
diagnosis is often based on clinical suspicion combined with
empirical decision making [3, 7].
No randomized controlled trials have investigated the
optimal treatment regimen for TBM. Current treatment
recommendations of 9–12 months of anti-TB treatment are
extrapolated from clinical trials of treatment for TBP, with
some guidelines advising a regimen consisting of rifampicin,
isoniazid, pyrazinamide, and ethambutol [8], while others
recommending that ethambutol can be replaced by either
streptomycin or ethionamide [9, 10].
The overall aim of this study was to describe the patient
characteristics, TB regimens, treatment outcomes, and prog-
nostic factors for HIV-positive patients with TBM and com-
pare these parameters to those of patients with TBEP or TBP.
2. Methods
2.1. The HIV/TB Study. TheHIV/TB study is a retrospective,
observational cohort study based on collaboration between
fifty four clinics and cohorts in Eastern Europe (EE), Cen-
tral/Northern Europe (CNE), Southern Europe (SE), and
Argentina (AR). The study included patients of 16 years or
older who were diagnosed with TB between January 2004
and December 2006 and who were either known to be HIV-
positive or diagnosed with HIV up to 3 months after their TB
diagnosis. Information was collected on standardized Case
Report Forms (CRFs, available at http://www.cphiv.dk), and
details of the study have previously been published [11]. In this
paper, we describe characteristics and outcomes for patients
with TBM, TBP, and TBEP.
Patients were categorized as having TBP if TB disease was
limited to either the lungs, pleura, or both. TBEP included
cases with either TB limited to at least one extrapulmonary
organ system (and potentially involving lungs and pleura),
including miliary TB or Mtb isolated from blood or bone
marrow. Disseminated TB was defined as involvement of at
least two extrapulmonary organ systems. Patients with TBM
were categorized separately regardless of having additional
pulmonary or other extrapulmonary involvement. The TBM
diagnosis was established by evidence of mycobacteria in
CSF (culture/AFB/PCR positive in CSF) or by empirical
decision of the clinician primarily based on a combination
of central nervous system symptoms (e.g., headache, altered
consciousness, dizziness, and nausea) and contemporaneous
documentation of extracranial TB.
Patients were categorized as having either a definite TB
diagnosis (culture/PCR positive), a probable TB diagnosis
(positive microscopy for acid-fast-bacilli (AFB)/granulo-
matous inflammation on histology), or a presumptive TB
diagnosis (based on clinical suspicion, where treatment was
initiated and not subsequently stopped because the TB
diagnosis was ruled out) as previously reported [11].
TB disease outcomes were classified as either “success,”
defined as either cure or treatment completed, or “fail,”
defined as either treatment failure, treatment deferred, treat-
ment interrupted, death, or loss to follow-up [12].
2.2. Statistical Methods. Descriptive statistics were used to
describe patients’ characteristics in the three TB disease
groups. Continuous variables were described using medians
and interquartile ranges, categorical variables using numbers
and percentages, and compared between diagnosis groups
using Mann-Whitney and 𝜒2-tests, respectively.
The date of TB diagnosis (baseline) was either the date
when a positive TB sample was obtained or the date when TB
treatment was initiated, whichever came first.
Kaplan-Meier estimation was used to describe the pro-
portion of patients who had died following TB diagnosis,
stratified by type of TB. Poisson regression models were used
to evaluate potential prognostic factors for the three groups of
TB patients separately, and the model included the following
variables that were identified a priori: geographical region,
age, CD4 cell count, usage of cART at time of TB, prior AIDS,
certainty of the TB diagnosis, presence of disseminated TB
disease, presence ofmultidrug resistant (MDR)TB, and usage
of a rifamycin in the initial anti-TB regimen. As the focus
was type of TB, interactions between type of TB and other
variables were investigated to determine if the relationships
differed, for example, if the relationship between age and
outcome differed depending on the type of TB diagnosis, and
stratified results presented.
Sensitivity analyses were performed to investigate
whether consistent results were found among patients with a
definitive diagnosis compared to those with a presumptive
or possible diagnosis and also to determine the relationship
between type of TB diagnosis and death in the first 12
months of follow-up, where mortality is known to be the
worst, particularly in Eastern Europe [13].
Follow-up was until date of death or the last date when
the patient was known to be alive or July 2010, whichever
occurred first. All analyses were performed using SAS,
version 9.3 (Statistical analysis Software, version 9.3, Cary,
NC, USA).
2.3. Ethical Approval. The overall study protocol was
approved by local ethics committees for each of the
participating clinics and cohorts as per local regulations and
was registered with the Danish Data Protection Agency.
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3. Results
3.1. Patient Characteristics and Treatment. Of the 1072
patientswith a classifiable TBdiagnosis, 100 (9.3%)were diag-
nosed with TBM, 371 (34.6%) with TBP, and 601 (56.1%) with
TBEP. HIV and TB clinical characteristics of the patients are
presented inTable 1.Theproportion of TBpatients presenting
with TBM varied between Europe and Argentina (10.4%,
10.4%, and 8.3% in Eastern, Central/Northern, and Southern
Europe, respectively compared with 4.3% in Argentina, 𝑃 =
0.072).
The majority of patients, 981 (91.5%), in all three groups
were known to be HIV-positive at the time of TB diagnosis.
Patients with TBM had significantly lower CD4 cell counts
compared to those with TBEP and TBP (𝑃 < 0.0001).
Significantly more patients with TBM had a prior AIDS
diagnosis other than TB: 39 (40.6%) compared to 112 (34.0%)
TBP and 161 (29.0%) TBEP patients (𝑃 = 0.043) (Table 1). A
significantly higher proportion of patients with TBM had an
AIDS defining illness within 3 months before or after their
TB diagnosis, 33 (33.0%) compared to 49 (13.2%) patients
with TBP and 89 (14.8%) with TBEP (𝑃 < 0.0001), possibly
reflecting their more advanced disease. In this time, only 3
AIDS defining illnesses occurred in>10 patients, oesophageal
candidiasis (𝑛 = 84), pneumocystis jiroveci pneumonia
(𝑛 = 25), and toxoplasmosis (𝑛 = 12), with other AIDS
defining illnesses occurring in 50 patients. Patients with TBM
were more likely to have one of the other, less frequently
occurring AIDS defining illnesses (15/33, 45.5%), compared
to those with TBP (13/49, 26.5%) or TBEP (22/89, 24.7%, 𝑃 =
0.078), although this was marginally statistically significant.
Among the 15 other diagnoses in those with TBM, there
were 4 diagnoses of AIDS dementia, 4 of HIV wasting, 3 of
extraocular cytomegalovirus, and 1 each of cryptococcosis,
cytomegalovirus retinitis, recurrent herpes simplex virus, and
progressive multifocal leucoencephalopathy. Of those known
to be HIV positive at time of TB diagnosis, 16 (16.7%) of the
TBM patients were receiving cART at time of TB diagnosis
compared with 74 (22.5%) and 87 (15.7%) in the TBP and
TBEP groups, 𝑃 = 0.035, and, of those with HIV-RNA
measurements available at time of TB diagnosis, 7 (21.9%) in
the TBM group had a viral load <400 copies/mL, compared
to 32 (26.9%) of those with TBP and 27 (13.8%) in the TBEP
group (𝑃 = 0.015) (Table 1).
TheTB diagnosis was less often definite for TBMpatients,
46 (46.0%), compared with 244 (65.8%) and 358 (59.6%) in
the TBP and TBEP groups, 𝑃 = 0.0037, and in 38 (38.0%)
patientsMtbwas documented in cerebrospinal fluid (CSF) by
microscopy (24), PCR (7), and/or culture (17). Severity of TB
disease was similar in the TBM and TBEP groups: 77 (77%)
and 515 (85.7%) had disseminated TB, respectively, and as per
definition, no patients in the TBP group (𝑃 = 0.038 between
TBM and TBEP). Of the TBM and TBEP patients, 69 (69.0%)
and 478 (79.5%) had TBP as well (Table 1).
Significantly more patients with TBM were classified as
having MDR-TB, 5 of 21 (23.8%) TBM patients with DST
available, compared to 14 of 96 (14.7%) with TBP and 8 of 139
(5.8%) with TBEP (𝑃 = 0.011). Significantly fewer patients
with TBM were treated with an initial regimen containing
TBM (N= 100)
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Figure 1: Outcomes following TB diagnosis.
isoniazid, pyrazinamide, and rifamycin (𝑃 = 0.016) andmore
patients in the TBM group received at least one 2nd line drug
(𝑃 = 0.0007) as part of their initial regimen compared with
the TBP and TBEP groups (Table 1).
3.2. Patient Outcome. Only 30 (30.0%) patients with a TBM
diagnosis attained successful treatment outcome (cure or
treatment completed) compared to 204 (55.2%) and 314
(52.3%) in the TBP and TBEP groups, respectively, 𝑃 <
0.0001. Sixty-one patients in the TBM group died (61.0%), 95
in the TBP group (25.6%), and 191 in the TBEP group (31.8%),
𝑃 < 0.0001 (Figure 1). The loss to follow-up rate during
therapy was the lowest for TBM patients and overall below
10% (Figure 1). The overall mortality rate was considerably
higher in the TBM group (39.3, 95%CI 29.4–49.2 per 100
person years of follow-up (PYFU)) compared to the TBEP
group (13.0, 95%CI 11.2–14.7 per 100 PYFU) and the TBP
group (6.4, 95%CI 5.1–7.7 per 100 PYFU). 207 deaths (59.7%)
occurred within the first 12 months following TB diagnosis;
this proportion was significantly higher for TBM (51, 83.6%)
compared to 44 (46.3%) for TBP and 112 (58.6%) for TBEP
(𝑃 < 0.0001). UsingKaplan-Meier estimation, the cumulative
probability of death at 12 months following TB diagnosis was
51.2% of those with TBM (95%CI 41.4–61.6%), compared to
12.3% for those with TBP (95%CI 8.9–15.7%) and 19.4% for
those with TBEP (95%CI 16.1–22.6) (𝑃 < 0.0001, log-rank
test) (Figure 2).
Table 2 shows the adjusted incidence rate ratios (aIRRs)
for a priori selected variables within each of the TB groups.
Patients from Eastern Europe (compared to all other regions
combined) had an approximately 5-fold increased risk of
dying following TBM, an 11-fold increased risk of dying fol-
lowing TBEP, and a 3-fold increased risk for dying following
TBP (test for interaction between geographic region and TB
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Table 1: Baseline characteristics of HIV/TB coinfected patients according to the type of TB.
TB meningitis Pulmonary TB Extrapulmonary TB Chi-squared test∗
N % N % N %
All 100 (9.3) 371 (34.6) 601 (56.1)
HIV characteristics
Gender
Male 74 (74.0) 234 (63.1) 422 (70.2) 0.028
Female 26 (26.0) 137 (36.9) 179 (29.8)
Race
White 75 (75.0) 224 (60.4) 377 (62.7) 0.026
Other 25 (25.0) 147 (39.6) 224 (37.3)
Origin1
Same country 75 (78.1) 300 (82.4) 436 (74.8)
0.0056Other Europe 6 (6.3) 8 (2.2) 13 (2.2)
Non-Europe 15 (15.6) 56 (15.4) 134 (23.0)
HIV risk2
IDU 55 (61.1) 183 (52.4) 279 (50.2)
0.17Heterosexual 25 (27.8) 118 (33.8) 178 (32.0)
Other 10 (11.1) 48 (13.8) 100 (17.9)
Region
Argentina 5 (5.0) 46 (12.4) 64 (10.7)
0.072South 17 (17.0) 75 (20.2) 114 (19.0)
Central 17 (17.0) 42 (11.3) 105 (17.5)
East 61 (61.0) 208 (56.1) 318 (52.9)
HBV
Negative 33 (33.0) 117 (31.5) 243 (40.4)
0.027Positive 5 (5.0) 31 (8.4) 51 (8.5)
Unknown 62 (62.0) 223 (60.1) 307 (51.1)
HCV
Negative 11 (11.0) 58 (15.6) 109 (18.1)
0.044Positive 35 (35.0) 106 (28.6) 210 (34.9)
Unknown 54 (54.0) 207 (55.8) 282 (46.9)
HIV before/at TB
Yes 96 (96.0) 329 (88.7) 556 (92.5) 0.027
HIV at least 3 months before TB3 72 (75.0) 258 (78.4) 396 (71.2) 0.060
Prior AIDS3
Yes 39 (40.6) 112 (34.0) 161 (29.0) 0.043
On cART3 16 (16.7) 74 (22.5) 87 (15.7) 0.035
Viral load4 (<400 cp/mL) 7 (21.9) 32 (26.9) 27 (13.8) 0.016
Median IQR Median IQR Median IQR
Age (years) 33 28–40 33 28–41 33 28–39 0.37
HIV VL4 (Log10 cp/mL) 5.0 3.5–5.6 4.5 2.6–5.3 4.9 4.1–5.6 0.0075
CD45 (/mm3) 113 40–269 236 101–492 143 58–304 <0.0001
Time HIV+ (months) 42 3–87 38 3–76 35 30–70 0.22
Date of TB diagnosis (month/year) 12/05 1/05–4/06 6/05 9/04–3/06 8/05 11/04–5/06 0.017
TB characteristics
Prior TB6
Yes 6 (6.7) 39 (11.5) 44 (7.7) 0.11
Disseminated TB 77 (77.0) — — 515 (85.7) 0.038∗∗
Certainty of TB diagnosis
Definite 4612 (46.0) 244 (65.8) 358 (59.6)
0.0037Probable 24 (24.0) 43 (11.6) 96 (16.0)
Presumptive 30 (30.0) 84 (22.6) 147 (24.5)
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Table 1: Continued.
TB meningitis Pulmonary TB Extrapulmonary TB Chi-squared test∗
N % N % N %
Symptoms
Yes 99 (99.0) 345 (93.0) 577 (96.0) 0.018
Fever 81 (81.8) 269 (78.6) 490 (84.8) 0.033
Weight loss 51 (51.5) 177 (51.3) 342 (59.3) 0.041
Cough with expectorate 26 (26.3) 229 (66.4) 201 (34.8) <0.0001
Dry cough 12 (12.1) 59 (17.1) 132 (22.9) 0.013
Other 79 (79.8) 161 (46.7) 357 (61.9) <0.0001
Anti-TB drug resistance
H-resistant7
Yes 7 (33.3) 24 (25.0) 18 (13.0) 0.016
Multidrug resistant7
Yes 5 (23.8) 14 (14.7) 8 (5.8) 0.011
Initial anti-TB treatment
RHZ 51 (51.0) 246 (66.3) 367 (61.1) 0.016
On 1st line drugs only8 35 (35.0) 209 (56.3) 307 (51.1) 0.0007
On 2nd line drug (s)9 65 (65.0) 162 (43.7) 294 (48.9)
Median IQR Median IQR Median IQR
Time since prior TB10 (months) 123 72–153 46 32–71 93 30–141 0.017
Weight11 (kg) 62 52–68 61 53–69 60 52–72 0.95
1Data available for 1043 (97.3%) at baseline. 2996 (92.9%) at baseline. 3Of 981HIV positive at baseline. 4347 patients (35.4%) of those HIV positive at baseline.
5788 (80.3%) of those HIV+ at baseline. 6Of those where information about prior TB diagnosis is known, 𝑁 = 1001. 7Data on resistance available for 256
patients. 8Ethambutol or streptomycin plus RHZ. 9Any other TB drug. 10Of those with a previous TB diagnosis. 11Of 703 (65.6%) with weightmeasured within 1
year of TB diagnosis. 12Mtb documented in cerebrospinal fluid (CSF) for 38 patients—microscopy (24), PCR (7), and/or culture (17). H: isoniazid, R: rifamycin,
and Z: pyrazinamide.
Baseline was defined as the date of TB diagnosis.
∗Global 𝑃 values comparing all three disease groups (TBM, TBP, and TBEP).
∗∗The 𝑃 value compares TBM and TBEP (by definition TBP cannot be disseminated).
IDU: injection drug user, HBV: hepatitis B, HCV: hepatitis C, HIV before/at TB: HIV diagnosed before TB diagnosis, HIV at least 3 months before TB: HIV
diagnosed at least 3 months before TB diagnosis, VL: viral load, and time HIV+: number of months the patients have been HIV+ (Median).
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group, 𝑃 = 0.0004). Prior AIDS was strongly associated
with death among TBM patients, and less pronounced so
among TBEP patients, but not among TBP patients. Being on
cART at TB diagnosis was associated with approximately 2/3
reduction in risk of dying in all three groups, whereas low
CD4 cell count at time of TB was an independent prognostic
factor for patients with TBP and TBEP but not for TBM
patients. TB resistance and usage of a rifamycin containing
initial regimen were not associated with death in any of the
groups, perhaps at least partially due to low numbers in some
of the groups.
3.3. Sensitivity Analyses. In a sensitivity analysis confined to
patients with a definitive diagnosis, consistent results were
found for all diagnoses to those shown in Table 2, although
the confidence intervals became very wide because of the
smaller number of patients included which makes any firm
conclusions about consistency difficult. For example, there
were 46 TBM patients with a definitive diagnosis of TB.
Patients from Eastern Europe had almost a 3-fold increased
incidence of death following TBM compared to patients from
all other regions compared (aIRR 2.96; 95%CI 1.09–8.06,
𝑃 = 0.029). Being on cART at TBM was associated with a
lower risk of death (aIRR 0.25; 95%CI 0.07–0.87, 𝑃 = 0.017).
An analysis further limited to the 38 patients whereMtb was
documented from the CSF showed similar results, but with
even less precision (data not shown).
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A sensitivity analysis was also performed limited to the
first 12 months of follow-up. As expected, as the majority of
patients with TBM died within 12 months, these results were
highly consistent with those shown in Table 2. The results
were also highly consistent for TBP. In the first 12 months
after diagnosis, there was less of a difference between regions
for TBEP; after adjustment, patients from Eastern Europe
had almost a 7-fold increased incidence of death compared
to other regions (aIRR 6.74; 95%CI 4.38–10.36, 𝑃 < 0.0001).
The other results were consistent with those shown in Table 2.
4. Discussion
The present study demonstrates that among HIV-positive
patients in Europe and Argentina, TBM is associated with
a high mortality rate, which is significantly higher than
among patients with either TBP or TBEP without meningeal
involvement. Approximately 51% of patients with TBM died
within 12 months of TB diagnosis, and our overall findings
are consistent with those from other continents [10]. A
randomized, controlled trial fromVietnam found that among
96 TBM patients coinfected with HIV, approximately 65%
died within 9 months after anti-TB treatment had been
initiated [3]. A retrospective study from Argentina found
a mortality rate of 63% during hospitalization among 101
TBM patients coinfected with HIV [6], while a study from
Zimbabwe documented 67% in-hospital mortality among 21
culture positive TBM patients coinfected with HIV [14].
Patients included in the previous studies were charac-
terized by severe immune suppression at the time of TBM
diagnosis and none had received cART. In the present study,
only 17% of TBM patients were on cART at TBM diagnosis,
and the majority of patients with TBM were immunosup-
pressed. Factors which were significantly associated with
death following TBM included region of follow-up (Eastern
Europe), having a prior (non-TB) AIDS diagnosis, and not
receiving cART.
Only 30% of TBMpatients were classified as having treat-
ment success defined as either cure or treatment completed.
These numbers areworrisome and can primarily be explained
by the very high mortality rate observed in this group. World
Health Organization has set targets of reducing TB mortality
rates by 50% by 2015 relative to 1990, a goal that is unlikely to
be met in Eastern Europe—a region where both the TB and
HIV epidemics are still increasing [15–18].
We have previously reported marked regional differences
in outcome following a TB diagnosis in general among HIV-
positive patients in Europe and Argentina. Approximately
30% of the patients in Eastern Europe died within the first
year after a TB diagnosis, which is 4-5-fold higher than
in Western Europe, but also 3-fold higher than in other
middle-income countries such as Argentina [11]. The present
study adds to the original report by documenting that these
regional differences were also present for the three TB
entities separately—and not least so for those presenting with
extrapulmonary involvement, namely, TBMandTBEP,which
in our setting to a large extent both could be characterized as
disseminated TB disease.
Fifty-four clinics and cohorts in the European Region and
Argentina contributed with data to this large study which has
enabled identification of 100 clinical cases of TBM coinfected
with HIV and included data from Eastern Europe, a region
from where data remain scarce. Although TBM is a relatively
rare disease, the size of the study has allowed for comparisons
of characteristics and patient outcomes as well as analyzing
regional differences in outcome.
Our study has several limitations. First of all, this was
a retrospective study with observational data. Secondly, as
an intrinsic limitation to TBM studies, TBM is a difficult
diagnosis to establish and, consistent with other studies, only
38.0% of TBM cases were based on positive findings in
the CSF. Further, the present study did not collect data on
CSF-leucocyte count, CSF protein, and CSF glucose, which
would have provided data to support the TBM diagnosis
in patients with negative cultures. Additionally, as relevant
differential diagnoses, 33% of TBM patients were diagnosed
with other opportunistic infections around time of the TB
diagnosis, including brain toxoplasmosis, progressive mul-
tifocal leucoencephalopathy and AIDS dementia. Finally,
we cannot rule out that the loss of follow-up rate could
have impacted the results, as also discussed previously [11].
Sensitivity analyses limited to the patients with a definite TB
diagnosis and including only the first 12 months of follow-up
showed consistent results with the main findings.
A large prospective observational cohort study of HIV-
positive patients presenting with TB is currently recruiting
patients in Europe and Latin America to help our under-
standing of how to improve the outcome for HIV- and TB-
coinfected patients including those with most severe disease
such as TBM [19].
5. Conclusion
In summary, HIV-positive patients with TBM in Europe and
Argentina are characterized by severe immune suppression
and by an alarmingly high mortality rate.The poor prognosis
following TBM is especially true for patients from Eastern
Europe and for patients with advanced HIV-infection, which
urgently calls for public health interventions to improve
patient management in terms of earlier diagnosis of HIV-
infection, timely and accurate TB diagnosis, optimal TB
treatment, and access to cART.
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